Drag

AGARWALEYE

Healthcare AGARWALEYE

432.75INR
10.60 ( 2.51%)

Last update at 2026-01-30 15:51:28

Day Range

414.00438.50
LowHigh

52 Week Range

327.00 568.00
LowHigh

Fundamentals

  • Previous Close 422.15
  • Market Cap 106150.05M
  • Volume268,836
  • P/E Ratio 453.72
  • EBITDA 4563.80M
  • Revenue TTM 17110.00M
  • Revenue Per Share TTM 57.40
  • Gross Profit TTM 7487.60M
  • Diluted EPS TTM 0.74

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Total Revenue
Net Income

Balance Sheet

Total Assets
Total Liabilities

Change in Cash

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Income before tax 1598.50M 1405.70M 835.91M 567.63M -490.51M
Net income 834.60M 1016.90M 940.97M 376.94M -554.78M
Total Revenue 17110.00M 13321.50M 10164.82M 6952.65M 4711.81M
Gross Profit 9912.90M 3853.82M 2961.41M 1908.25M 2872.87M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 36715.70M 27826.17M 18251.74M 10261.34M 7869.87M
Intangible assets 4572.70M 2677.71M 2181.28M 387.55M 230.10M
Other current assets 683.80M 1238.47M 366.77M 378.85M 246.87M
Deferred long term liab - - - - -
Non current assets other - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Change in Cash 1462.92M -152.32M 273.60M 444.10M 552.12M
Operating Cash 3314.40M 3459.58M 2331.06M 1643.28M 991.59M
Free Cash Flow 227.90M 1136.43M 753.05M 937.40M -273.95M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change Price Market Cap (M) P/E Ratio
AGARWALEYE
AGARWALEYE 		10.60 2.51% 432.75 106150.05 453.72
POLYMED
Poly Medicure Limited 		-116.50 -7.75% 1386.00 180105.67 49.83
TARSONS
Tarsons Products Limited 		8.66 4.20% 215.00 11941.79 57.98
LAXMIDENTL
LAXMIDENTL 		-4.29 -2.07% 203.28 -

Profile

Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens. The company also provides surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty, and surgeries for the treatment of glaucoma and pterygium; doctor consultation services; and diagnostic services for eye disorders along with non-surgical treatments, including retinal laser therapy and dry eye treatment services. It also sells glasses, lenses, contact lenses, and frames; and eye care-related pharmaceutical products. The company was incorporated in 2010 and is based in Chennai, India.

AGARWALEYE

3rd Floor, Buhari Towers, Chennai, India, 600006

Key Executives

Name Title Year Born
Dr. Adil Agarwal M.B.B.S, M.S, MBA CEO & Whole-Time Director 1983
Dr. Anosh Agarwal M.B.B.S, MBA, MS Ophthal COO & Wholetime Director 1984
Mr. Thanikainathan Arumugam VP of Corporate Affairs, Company Secretary & Compliance Officer NA
Mr. Yashwanth Venkat Chief Financial Officer 1985
Dr. Ashvin Agarwal Chief Clinical Officer 1983
Dr. Ashar Agarwal Chief Business Officer 1985
Dr. Vandana Jain M.D. Chief Strategy Officer NA
Mr. Rahul Agarwal Chief Operating Officer- Hospital Operations NA
Ms. Aashna Dharia Head of Investor Relations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data ("EODHD") on an 'as is' basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.